Literature DB >> 15050943

Acute rheumatic fever: a chink in the chain that links the heart to the throat?

Malcolm McDonald1, Bart J Currie, Jonathan R Carapetis.   

Abstract

Acute rheumatic fever (ARF) remains a major problem in tropical regions, resource-poor countries, and minority indigenous communities. It has long been thought that group A streptococcal (GAS) pharyngitis alone was responsible for acute rheumatic fever; this belief has been supported by laboratory and epidemiological evidence gathered over more than 60 years, mainly in temperate climates where GAS skin infection is uncommon. GAS strains have been characterised as either rheumatogenic or nephritogenic based on phenotypic and genotypic properties. Primary prevention strategies and vaccine development have long been based on these concepts. The epidemiology of ARF in Aboriginal communities of central and northern Australia challenges this view with reported rates of ARF and rheumatic heart disease (RHD) that are among the highest in the world. GAS throat colonisation is uncommon, however, and symptomatic GAS pharyngitis is rare; pyoderma is the major manifestation of GAS infection. Typical rheumatogenic strains do not occur. Moreover, group C and G streptococci have been shown to exchange key virulence determinants with GAS and are more commonly isolated from the throats of Aboriginal children. We suggest that GAS pyoderma and/or non-GAS infections are driving forces behind ARF in these communities and other high-incidence settings. The question needs to be resolved as a matter of urgency because current approaches to controlling ARF/RHD in Aboriginal communities have clearly been ineffective. New understanding of the pathogenesis of ARF would have an immediate effect on primary prevention strategies and vaccine development.

Entities:  

Mesh:

Year:  2004        PMID: 15050943     DOI: 10.1016/S1473-3099(04)00975-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  66 in total

1.  Streptococcus pyogenes Ser/Thr kinase-regulated cell wall hydrolase is a cell division plane-recognizing and chain-forming virulence factor.

Authors:  Vijay Pancholi; Gregory Boël; Hong Jin
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

Review 2.  Toward a genome-wide systems biology analysis of host-pathogen interactions in group A Streptococcus.

Authors:  James M Musser; Frank R DeLeo
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

3.  A new Toll-road from environment to genes for rheumatic fever?

Authors:  Ralf R Schumann; Rolf Keitzer
Journal:  J Mol Med (Berl)       Date:  2005-06-24       Impact factor: 4.599

Review 4.  Rheumatic fever and its management.

Authors:  Antoinette M Cilliers
Journal:  BMJ       Date:  2006-12-02

5.  Ethnic differences for developing rheumatic fever in a low-income group living in Hawaii.

Authors:  David K Kurahara; Andrew Grandinetti; Judith Galario; D Venu Reddy; Angela Tokuda; Susan Langan; Brian Tanabe; Kara S Yamamoto; Karen M Yamaga
Journal:  Ethn Dis       Date:  2006       Impact factor: 1.847

Review 6.  Sore throat.

Authors:  Tim Kenealy
Journal:  BMJ Clin Evid       Date:  2007-11-20

Review 7.  Strategies in the development of vaccines to prevent infections with group A streptococcus.

Authors:  Michael F Good; Michael R Batzloff; Manisha Pandey
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

8.  A dramatic decline in university hospital admissions of acute rheumatic fever in the eastern region of Saudi Arabia.

Authors:  Mohammed Fakhry Abdul-Mohsen; Amer A Lardhi
Journal:  J Saudi Heart Assoc       Date:  2011-01-08

9.  The prospect of vaccination against group A beta-hemolytic streptococci.

Authors:  Karen L Kotloff
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

Review 10.  Prevention and treatment of rheumatic heart disease in the developing world.

Authors:  Andrew C Steer; Jonathan R Carapetis
Journal:  Nat Rev Cardiol       Date:  2009-09-15       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.